{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:58:58Z","timestamp":1793285938987,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.clinthera.2011.04.012","type":"journal-article","created":{"date-parts":[[2011,6,13]],"date-time":"2011-06-13T01:36:44Z","timestamp":1307929004000},"page":"500-510","source":"Crossref","is-referenced-by-count":18,"title":["Comparative Bioavailability of 2 Tablet Formulations of Levodopa\/Benserazide in Healthy, Fasting Volunteers: A Single-Dose, Randomized-Sequence, Open-Label Crossover Study"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct01327261","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Guillermo A.","family":"Keller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Czerniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bertuola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G.","family":"Spatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aria R.","family":"Assefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Di Girolamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.04.012_bib1","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","article-title":"Parkinson's disease","volume":"373","author":"Lees","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2011.04.012_bib2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"De Lau","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-211-73574-9_12","article-title":"Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study","volume":"72","author":"Jellinger","year":"2007","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.clinthera.2011.04.012_bib4","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/BF01485901","article-title":"Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems","volume":"38","author":"Ehringer","year":"1960","journal-title":"Klin Wochenshr"},{"key":"10.1016\/j.clinthera.2011.04.012_bib5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/oxfordjournals.bmb.a070990","article-title":"Dopamine in the basal ganglia: its role and therapeutic implications (including the clinical use of l-dopa)","volume":"29","author":"Hornykiewicz","year":"1973","journal-title":"Br Med Bull"},{"key":"10.1016\/j.clinthera.2011.04.012_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/mds.10115","article-title":"Dopamine miracle: from brain homogenate to dopamine replacement","volume":"17","author":"Hornykiewicz","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2011.04.012_bib7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","article-title":"Aromatic amino acids and modification of parkinsonism","volume":"276","author":"Cotzias","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.04.012_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of parkinsonism\u2014chronic treatment with l-dopa","volume":"280","author":"Cotzias","year":"1969","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clinthera.2011.04.012_bib9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/mds.20243","article-title":"Levodopa in the treatment of Parkinson's disease: current controversies","volume":"19","author":"Olanow","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2011.04.012_bib10","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMct0800326","article-title":"Levodopa for the treatment of Parkinson's disease","volume":"359","author":"Lewitt","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.04.012_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0733-8619(18)30213-5","article-title":"The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras","volume":"10","author":"Hoehn","year":"1992","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clinthera.2011.04.012_bib12","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1212\/WNL.43.10.1918","article-title":"Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project","volume":"43","author":"Uitti","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2011.04.012_bib13","first-page":"23","article-title":"The long term therapeutic effect of levodopa in the treatment of Parkinsonism","volume":"3","author":"Godwin-Austen","year":"1973","journal-title":"Adv Neurol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/242463a0","article-title":"Active transport of l-dopa in the intestine","volume":"242","author":"Wade","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2011.04.012_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2125.1986.tb02913.x","article-title":"The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations","volume":"22","author":"Hardie","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0163-7258(02)00325-X","article-title":"L-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system","volume":"97","author":"Misu","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.04.012_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0024-3205(75)90248-9","article-title":"3-O-Methyldopa uptake and inhibition of l-dopa at the blood\u2013brain barrier","volume":"17","author":"Wade","year":"1975","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2011.04.012_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002826-198403000-00002","article-title":"Pharmacokinetics of levodopa","volume":"7","author":"Nutt","year":"1984","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003088-199630060-00004","article-title":"Pharmacokinetic optimisation in the treatment of Parkinson's disease","volume":"30","author":"Contin","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2011.04.012_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.410180505","article-title":"The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism","volume":"18","author":"Nutt","year":"1985","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib21","series-title":"Pharmacotherapy: A Pathophysiologic Approach","first-page":"1089","article-title":"Parkinson's disease","author":"Nelson","year":"2005"},{"key":"10.1016\/j.clinthera.2011.04.012_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0022-3565(25)32511-5","article-title":"The site of dopamine formation in rat striatum after l-dopa administration","volume":"217","author":"Hefti","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2011.04.012_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0378-4347(00)80507-1","article-title":"Routine determination of plasma catecholamines using reversed-phase, ion-pair high-performance liquid chromatography with electrochemical detection","volume":"231","author":"Davies","year":"1982","journal-title":"J Chromatogr"},{"key":"10.1016\/j.clinthera.2011.04.012_bib27","series-title":"Handbook of Basic Pharmacokinetics\u2014Including Clinical Applications","author":"Ritschel","year":"2004"},{"key":"10.1016\/j.clinthera.2011.04.012_bib28","series-title":"Practical Nonparametric Statistics","year":"1980"},{"key":"10.1016\/j.clinthera.2011.04.012_bib29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2307\/2532191","article-title":"Estimating treatment means in a mixed-effect ANOVA model for bioequivalence studies","volume":"49","author":"Hsuan","year":"1993","journal-title":"Biometrics"},{"key":"10.1016\/j.clinthera.2011.04.012_bib30","series-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","author":"Chow","year":"2000"},{"key":"10.1016\/j.clinthera.2011.04.012_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability","volume":"15","author":"Schuirmann","year":"1987","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.clinthera.2011.04.012_bib32","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1080\/03610928308828634","article-title":"A new procedure for testing equivalence in comparative bioavailability and other clinical trials","volume":"12","author":"Anderson","year":"1983","journal-title":"Commun Stat Theory Methods"},{"key":"10.1016\/j.clinthera.2011.04.012_bib33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00228-003-0680-5","article-title":"Pharmacokinetic\u2013pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa\/benserazide","volume":"59","author":"Silveira","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0939-6411(98)00022-8","article-title":"Comparative single- and multiple-dose pharmacokinetics of levodopa O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects","volume":"46","author":"Gasser","year":"1998","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.clinthera.2011.04.012_bib35","first-page":"109","article-title":"Bioequivalence","volume":"45","author":"Marzo","year":"1995","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2011.04.012_bib36","first-page":"623","article-title":"Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa\/carbidopa 250\/25 mg) in Parkinson s disease: a single dose study [in Spanish]","volume":"131","author":"Chan\u00e1","year":"2003","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.clinthera.2011.04.012_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF03189968","article-title":"Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies","volume":"16","author":"Shah","year":"1991","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2011.04.012_bib38","author":"Homedes"},{"key":"10.1016\/j.clinthera.2011.04.012_bib40","first-page":"302","article-title":"Pharmacokinetic and metabolic studies of the decarboxylase inhibitor benserazide in animals and man","volume":"28","author":"Schwartz","year":"1978","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2011.04.012_bib41","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00702-007-0773-x","article-title":"Comparison of 200 mg retarded release levodopa\/carbidopa\u2014with 150 mg levodopa\/carbidopa\/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease","volume":"114","author":"M\u00fcller","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.clinthera.2011.04.012_bib42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1468-1331.1999.tb00015.x","article-title":"The effect of tolcapone on the pharmacokinetics of benserazide","volume":"6","author":"Jorga","year":"1999","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000067025","article-title":"Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers","volume":"49","author":"Crevoisier","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003088-197601050-00001","article-title":"Clinical pharmacokinetics of levodopa in Parkinson's disease","volume":"1","author":"Bianchine","year":"1976","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2011.04.012_bib45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2362.1971.tb00637.x","article-title":"Absorption and metabolism of l-dopa by the human stomach","volume":"I","author":"Rivera-Calimlim","year":"1971","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clinthera.2011.04.012_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00544017","article-title":"Intestinal absorption of levodopa in man","volume":"25","author":"Gundert-Remy","year":"1983","journal-title":"Eur J Clin Phamacol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib47","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jps.2600701018","article-title":"Dosage form design for improvement of bioavailability of levodopa V: absorption and metabolism of levodopa in intestinal segments of dogs","volume":"70","author":"Sasahara","year":"1981","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2011.04.012_bib48","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/0016-5085(86)90200-3","article-title":"Influence of food and marker length on gastric emptying of indigestible radiopaque markers in healthy humans","volume":"91","author":"Smith","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2011.04.012_bib49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.38.3.419","article-title":"Erratic gastric emptying of levodopa may cause \u201crandom\u201d fluctuations of parkinsonian mobility","volume":"38","author":"Kurlan","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2011.04.012_bib50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(03)00307-7","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"2","author":"Pfeiffer","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib51","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mds.1203","article-title":"Gastric emptying time and gastric motility in patients with Parkinson's disease","volume":"16","author":"Hardoff","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2011.04.012_bib52","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.46.4.1051","article-title":"Gastric emptying in Parkinson's disease: patients with and without response fluctuations","volume":"46","author":"Djaldetti","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2011.04.012_bib53","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/BF01271202","article-title":"Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off [published correction appears in J Neural Transm. 1997;104:311]","volume":"103","author":"Murata","year":"1996","journal-title":"J Neural Transm"},{"key":"10.1016\/j.clinthera.2011.04.012_bib54","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.46.4.1051","article-title":"Gastric emptying in Parkinson's disease: patients with and without response fluctuations","volume":"46","author":"Djaldetti","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2011.04.012_bib55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2125.1990.tb03601.x","article-title":"The influence of levodopa on gastric emptying in man","volume":"29","author":"Robertson","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib56","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/BF01271202","article-title":"Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off","volume":"103","author":"Murata","year":"1996","journal-title":"J Neural Transm"},{"key":"10.1016\/j.clinthera.2011.04.012_bib57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00003088-198713030-00002","article-title":"Clinical pharmacokinetics of anti-parkinsonian drugs","volume":"13","author":"Cedarbaum","year":"1987","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2011.04.012_bib58","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.0954-6820.1975.tb19565.x","article-title":"Intestinal decarboxylation of orally administered l-dopa","volume":"198","author":"Andersson","year":"1975","journal-title":"Acta Med Scand"},{"issue":"12 Suppl 6","key":"10.1016\/j.clinthera.2011.04.012_bib59","first-page":"S31","article-title":"Levodopa therapeutics: new treatment strategies","volume":"43","author":"LeWitt","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2011.04.012_bib60","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00561903","article-title":"Systemic activity of orally administered l-dopa in the elderly Parkinson patient","volume":"17","author":"Evans","year":"1980","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib61","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJM198402233100802","article-title":"The \u201con-off\u201d phenomenon in Parkinson's disease: relation to levodopa absorption and transport","volume":"310","author":"Nutt","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.04.012_bib62","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1749-6632.1971.tb46895.x","article-title":"Metabolism and absorption of L-3,4-dihydroxyphenyl-alanine in patients with Parkinson\u2032s disease","volume":"179","author":"Bianchine","year":"1971","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinthera.2011.04.012_bib63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000116173","article-title":"Bioavailability of l-dopa after Madopar HBS admininistration in healthy volunteers","volume":"27","author":"Crevoisier","year":"1987","journal-title":"Eur Neurol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib64","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/mds.870110412","article-title":"Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa\/levodopa): a single-dose study","volume":"11","author":"Pahwa","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2011.04.012_bib65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","article-title":"Pharmacokinetic optimization in the treatment of Parkinson's disease: an update","volume":"45","author":"Nyholm","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2011.04.012_bib66","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/WNF.0b013e3181d47849","article-title":"Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease","volume":"33","author":"Adamiak","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib67","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.neulet.2004.04.012","article-title":"Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease","volume":"363","author":"Muhlack","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.clinthera.2011.04.012_bib68","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.clinthera.2009.10.019","article-title":"Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa\/benserazide: a single-center, phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects","volume":"31","author":"Nunes","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2011.04.012_bib69","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000007918","article-title":"Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease","volume":"39","author":"Dingemanse","year":"1998","journal-title":"Eur Neurol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib70","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1440-1681.2006.04484.x","article-title":"d-Dopa is unidirectionally converted to l-dopa by D-amino acid oxidase, followed by dopa transaminase","volume":"33","author":"Wu","year":"2006","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.clinthera.2011.04.012_bib71","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbrc.2007.01.181","article-title":"Structural basis of d-dopa oxidation by D-amino acid oxidase: alternative pathway for dopamine biosynthesis","volume":"355","author":"Kawazoe","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2011.04.012_bib72","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1353-8020(00)00005-5","article-title":"Levodopa in plasma correlates with body weight of parkinsonian patients","volume":"6","author":"M\u00fcller","year":"2000","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.clinthera.2011.04.012_bib73","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s10072-003-0125-z","article-title":"Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?","volume":"24","author":"Martinelli","year":"2003","journal-title":"Neurol Sci"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811001950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811001950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T03:53:18Z","timestamp":1741233198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811001950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0149291811001950"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.04.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}